ECPC seeks to raise awareness among the political world about specific problems encountered in the field of paediatric oncology to improve children’s health in Europe.

A new Paediatric Regulation entered into force in the European Union (EU) on 26 January 2007.

The objective of the Paediatric Regulation is to improve the health of children in Europe by:

• facilitating the development and availability of medicines for children aged 0 to 17 years,
• ensuring that medicines for use in children are of high quality, ethically researched, and authorised appropriately,
• improving the availability of information on the use of medicines for children,

without:

• subjecting children to unnecessary trials,
• or delaying the authorisation of medicines for use in adults.

Please find the following helpful documents and links:

• ECPC Newsletter - Young People and Cancer: A Call for Action (February 2011)
• ECPC Member Brief (Aug 2007)
• Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use;
• Regulation (EC) No 1902/2006 — an amending regulation in which changes to the original text were introduced relating to decision procedures for the European Commission.
• Medicines for Children section of the EMEA website
• EMEA leaflet "Better Medicines for Children"
  
• 'Medicines for children' section of the DG Enterprise and Industry (European Commission) website
  
• ECPC Paediatric Regulation Presentation
  
• ECPC Paediatrics Position Paper (June 2005)
• Commission proposal on Paediatric medicines
• EU press release on commission proposal on Paediatric medicines
• EPHA Briefing on the Draft Proposal for Paediatric Medicines